Login / Signup

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Torben PlesnerHendrik-Tobias ArkenauFrancesca GayMonique C MinnemaMario BoccadoroPhillipe MoreauJamie CavenaghAurore PerrotJacob P LaubachJakub KrejcikTahamtan AhmadiCarla de BoerDiana ChenChristopher ChiuJordan M SchecterPaul Gerard Richardson
Published in: British journal of haematology (2019)
Keyphrases
  • multiple myeloma
  • open label
  • placebo controlled
  • double blind
  • low dose
  • high dose
  • clinical trial
  • randomized controlled trial
  • study protocol
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • hodgkin lymphoma